Rhumbline Advisers Durect Corp Transaction History

Rhumbline Advisers

$103 Billion
Q1 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$0.38 - $0.64 $79,480 - $133,862	-209,160 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$0.55 - $0.98 $1,540 - $2,744	2,800 Added 1.36%	209,160 $140,000
Q4 2021 Feb 10, 2022	SELL	$0.9 - $1.31 $4,461 - $6,493	-4,957 Reduced 2.35%	206,360 $203,000
Q3 2021 Nov 12, 2021	BUY	$1.21 - $1.61 $2,671 - $3,554	2,208 Added 1.06%	211,317 $270,000
Q2 2021 Aug 05, 2021	SELL	$1.6 - $2.02 $20,833 - $26,302	-13,021 Reduced 5.86%	209,109 $341,000

Q1 2021 May 06, 2021	SELL	$1.86 - $2.87 $10,713 - $16,531	-5,760 Reduced 2.53%	222,130 $440,000
Q4 2020 Feb 10, 2021	BUY	$1.65 - $2.43 $33,462 - $49,280	20,280 Added 9.77%	227,890 $472,000
Q3 2020 Nov 12, 2020	SELL	$1.6 - $2.35 $57,952 - $85,117	-36,220 Reduced 14.85%	207,610 $355,000
Q2 2020 Aug 13, 2020	BUY	$1.33 - $2.76 $324,293 - $672,970	243,830 New	243,830 $566,000
Q2 2019 Aug 14, 2019	SELL	$0.51 - $0.86 $102,306 - $172,516	-200,600 Closed	0 $0
Q1 2019 May 01, 2019	SELL	$0.51 - $0.82 $1,879 - $3,021	-3,685 Reduced 1.8%	200,600 $126,000
Q4 2018 Jan 31, 2019	BUY	$0.48 - $1.1 $30,232 - $69,283	62,985 Added 44.58%	204,285 $99,000
Q3 2018 Nov 07, 2018	SELL	$1.06 - $1.69 $10,759 - $17,153	-10,150 Reduced 6.7%	141,300 $155,000
Q2 2018 Aug 06, 2018	BUY	$1.56 - $2.51 $32,487 - $52,270	20,825 Added 15.94%	151,450 $236,000
Q1 2018 May 02, 2018	SELL	$0.91 - $2.24 $1,842 - $4,536	-2,025 Reduced 1.53%	130,625 $280,000
Q4 2017 Feb 09, 2018	SELL	$0.78 - $2.1 $30,609 - $82,410	-39,243 Reduced 22.83%	132,650 $122,000
Q3 2017 Nov 06, 2017	BUY	$1.55 - $1.82 $266,434 - $312,845	171,893	171,893 $304,000

Others Institutions Holding DRRX

# of Institutions

Shares Held

559K

Call Options Held

Put Options Held

View Full List

About DURECT CORP

Ticker DRRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 227,794,000
Market Cap $294M
Description
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogeno...

More about DRRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account